Prognostic Role of MELD-Lactate in Cirrhotic Patients’ Short- and Long-Term Prognosis, Stratified by Causes of Cirrhosis

Table 2

Model discrimination for mortality in the whole study population.

Mortality	15-day mortality				5-year mortality
Prognostic models	AUROC (95% CI)	Cut-off point	Sensitivity	Specificity	AUROC (95% CI)	Cut-off point	Sensitivity	Specificity
Child-Pugh	0.611 (0.558–0.665)	11	0.63	0.56	0.575 (0.523–0.627)	10	0.74	0.38
SOFA	0.802 (0.757–0.846)	10	0.78	0.71	0.669 (0.620–0.719)	10	0.52	0.72
CLIF-SOFA	0.794 (0.748–0.840)	11	0.74	0.75	0.684 (0.636–0.732)	10	0.62	0.69
MELD	0.775 (0.728–0.822)	20	0.69	0.74	0.721 (0.674–0.767)	17	0.63	0.73
MELD-LA	0.808 (0.765–0.852)	15	0.81	0.65	0.713 (0.666–0.760)	14	0.70	0.64

DeLong test was used to compare the AUC between MELD-LA and other clinical models. AUROC, area under the receiver operating characteristic curve; CI, confidence interval; SOFA, sequential organ failure assessment; CLIF-SOFA, chronic liver failure-sequential organ failure assessment; MELD, model for end-stage liver disease; MELD-LA, model for end-stage liver disease-lactate.